Evidence map›Paper›PMID 30605261›Full record

ReviewAdvanced healthcare materials2019

Organ-on-a-Chip for Cancer and Immune Organs Modeling.

Wujin Sun, Zhimin Luo, Junmin Lee, Han-Jun Kim, KangJu Lee, Peyton Tebon, Yudi Feng, Mehmet R Dokmeci, Shiladitya Sengupta, Ali Khademhosseini

Erratum issuedOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced healthcare materials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
9.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 208 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Microphysiological systems as models for immunologically 'cold' tumors.Frontiers in cell and developmental biology · 2024
    Review
  18. Review
  19. Review
  20. Engineered organoids for biomedical applications.Advanced drug delivery reviews · 2023
    Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Wujin SunDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Zhimin LuoDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Junmin LeeDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Han-Jun KimDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
KangJu LeeDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Peyton TebonDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Yudi FengDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Mehmet R DokmeciDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Shiladitya SenguptaBrigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Ali KhademhosseiniDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.ORCID 0000-0001-6322-8852
California NanoSystems Institute · USBrigham and Women's Hospital · US

Funding

Engineering personalized micro-tumor ecosystemsU01CA214411 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI, SENGUPTA, SHILADITYA · 2017 to 2021
$3.5M
Whitlockite nanoparticle-based immunotherapy for bone metastasisR01CA236702 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JANG, HAE LIN, SENGUPTA, SHILADITYA · 2019 to 2023
$2.7M
Research Supplements to Promote DiversityR01GM126571 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, YE, JING YONG · 2018 to 2021
$1.3M
NCI NIH HHS R01 CA236702NCI NIH HHS U01 CA214411NIGMS NIH HHS R01 GM126571
6 · The paper itself

Abstract

Bridging the gap between findings in preclinical 2D cell culture models and in vivo tissue cultures has been challenging; the simple microenvironment of 2D monolayer culture systems may not capture the cellular response to drugs accurately. Three-dimensional organotypic models have gained increasing interest due to their ability to recreate precise cellular organizations. These models facilitate investigation of the interactions between different sub-tissue level components through providing physiologically relevant microenvironments for cells in vitro. The incorporation of human-sourced tissues into these models further enables personalized prediction of drug responses. Integration of microfluidic units into the 3D models can be used to control their local environment, dynamic simulation of cell behaviors, and real-time readout of drug testing data. Cancer and immune system related diseases are severe burdens to our health care system and have created an urgent need for high-throughput, and effective drug development plans. This review focuses on recent progress in the development of "cancer-on-a-chip" and "immune organs-on-a-chip" systems designed to study disease progression and predict drug-induced responses. Future challenges and opportunities are also discussed.

Indexed as

Lab-On-A-Chip DevicesModels, ImmunologicalOrganoidsTissue EngineeringCell Culture TechniquesNeoplasmsTumor Microenvironmentcancerdrug screeningimmune systemorganoidsorgan-on-a-chip

Identifiers

PMID30605261
PMCPMC6424124
OpenAlexW2907304027

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.